Parameter
| Biomarker | GFAP | Full name | Glial Fibrillary Acidic Protein | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Pathological Confirmation, Subtype Differentiation |
| Disease | Amyotrophic Lateral Sclerosis | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | CSF/Plasma (SIMOA, Immunoassay) | ||
| Pathobiological Mechanisms | Released after astrocyte activation, involved in blood-brain barrier maintenance and neuroinflammation regulation. | ||||
| Clinical Availability Status | Research validation stage | ||||
| Notes and Dynamics | Plasma GFAP levels in C9orf72 mutant ALS patients are 35% higher than in sporadic ALS, positively correlated with the degree of astrocyte activation in the brain; can assist in distinguishing ALS from Frontotemporal Dementia (FTD). | ||||